Our lead program
Vigeo’s lead drug program, currently being studied in a Phase 1 trial, is VT1021, a small peptide agent derived from PSAP. VT1021 triggers Tsp-1 production, which reprograms the tumor microenvironment and makes it inhospitable for tumor growth.
Pre-clinical results have demonstrated that VT1021, when administered systemically, can inhibit tumor growth in animal models at both the primary and metastatic sites. VT1021 is currently being evaluated in a Phase 1 clinical trial that assesses the drug’s safety, tolerability, and preliminary anti-tumor efficacy – as a monotherapy in combination with other cancer therapies.
The trial’s dose escalation phase was launched in late 2017, and the expansion phase will initiate in early 2019. The dose expansion phase aims to confirm the tolerability of VT1021 against specific tumor types, including triple negative breast cancer, ovarian cancer, pancreatic cancer, glioblastoma, and other advanced solid tumors.
Meanwhile, pipeline programs are on track to generate novel therapies that will further validate Vigeo’s TIME-targeting approach.